Ademi LLP is investigating GlycoMimetics (NASDAQ: GLYC) for possible breaches of fiduciary duty and other violations of law in its transaction with Crescent.
Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.
Under the agreement, GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company and Crescent stockholders are expected to own approximately 96.9% of the company. The percentage of the company that GlycoMimetics’s stockholders will own is subject to adjustment based on the amount of GlycoMimetics’s net cash at the closing date.
The transaction agreement unreasonably limits competing transactions for GlycoMimetics by imposing a significant penalty if GlycoMimetics accepts a competing bid. GlycoMimetics insiders will receive substantial benefits as part of change of control arrangements.
We are investigating the conduct of GlycoMimetics’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
If you own GlycoMimetics common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or here.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029718656/en/
